Principal risk factors in patients with liver cirrhosis in Ciego de Avila
Abstract
An observational, descriptive, retrospective, cross sectional study was carried out. An observational, descriptive, retrospective, cross sectional study was carried out with the aim to determine the main risk factors in patients with liver cirrhosis in Ciego de Avila, from January, 2002 to December, 2012. 119 patients with this illness were diagnosed, prevailing fundamentally in the group of 60 years andmore with 69 cases (57.9 %) and 65 (54.6 %) of the masculine sex.The risk factors that frequently were present in patients with liver cirrhosis were the chronic hepatitis C virus in 44 patients (36.9 %) and the alcoholism in 17 (14.2 %). In 23 cases (19.3 %) it was not possible to require the possible etiologic factor of this disease, therefore they qualified as unknown or cryptogenetic cause. Most of the patients were in the compensated phase of the illness, being the asthenia, and the loss of weight the initiate symptoms. The ascites was the complication more often observed (31.9 %) and 41.1% of patients presented a moderate liver failure (Child-Pugh class B) at the diagnosis moment
Downloads
Author Biographies
Alberto Martínez Sarmiento
Fernando Valdivia Rodríguez
Milagros Cárdenas Quintana
References
García Buey L, González Mateos F, Moreno Otero R. Cirrosis hepática. Medicine. 2012; 11(11): 625-63.
Dorta GuridiI Z, Castellanos Fernández M, Nodarse Cuní H, Arús Soler E, Pérez Triana F, González Fabián L. Tolerancia del tratamiento con interferón estándar y ribavirina en pacientes cirróticos por virus de la hepatitis C. Rev Cubana Med. 2010; 49(2)1-10.
Tae Suk K, Koo Baik S, Hwan Yoon J, Youn Cheong J, Han Paik Y, Hyeong Lee Ch, et al. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012; 18:1-21.
Zatoński WA, Sulkowska U, Mańczuk M, Rehm J, Boffetta P, Lowenfels AB, et al. Liver cirrhosis mortality in Europe, with special attention to central and eastern Europe. Eur Addict Res. 2010; 16:193–201.
Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review Article: The reversibility of cirrhosis. Aliment Pharmacol Ther. 2012; 36(9):824-832.
Wolf DC. Definition, epidemiology and etiology of cirrhosis [Internet]. ©Medscape; 1994-2013 [actualizado 20 Aug 2012; citado 20 Feb 2013] [aprox. 26 pantallas]. Disponible en: http://www. emedicine.medscape.com/article/185856-overview
Hernández Gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012; 107(3):418-427.
Rahimi RS, Rockey DC. Complications of cirrhosis. Curr Opin Gastroenterol. 2012; 28(3):223-229.
Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis. Aliment Pharmacol Ther. 2010; 32(11):1343-1350.
Landa Galván HV, Milke García MP, León Oviedo C, Gutiérrez Reyes G, Higuera de la Tijera F, Pérez Hernández JL, et al. Evaluación del estado nutricional de pacientes con cirrosis hepática alcohólica atendidos en la clínica de hígado del Hospital General de México. Nutr Hosp. 2012; 27(6):2006-2014.
Meléndez CA, Meléndez JJ. Main causes and factors associated with liver cirrhosis in patients in the General Hospital of Zone 2 of Chiapas, Mexico. Medwave. 2012; 12(7):e5454.
Mosqueira JR, Montiel JB, Rodríguez D, Monge E. Evaluación del test diagnóstico índice número de plaquetas/diámetro mayor del bazo, como predictor de la presencia de várices esofágicas en cirrosis hepática. Rev Gastroenterol Perú. 2011; 31(1):11-16.
Castellanos Suárez J, Infante Velásquez M, Pérez Lorenzo M, Umpiérrez García I, Fernández Báez A. Caracterización clínica de pacientes con cirrosis hepática en el Hospital Militar Docente “Dr. Mario Muñoz”, de Matanzas. Rev Méd Electr [Internet]. 2012 [citado 22 Feb 2013]; 34(6): [aprox. 9 p.]. Disponible en: http://www.revmatanzas.sld.cu/revista%20medica/ano%202012/vol6%202012/tema01.htm
Lebroc Pérez D, Reina Alfonso BE, Camacho Assef JA, Massíp Ramírez M. Caracterización clínica de los pacientes con cirrosis hepática en el Hospital Provincial Docente “Dr. Antonio Luaces Iraola”. MediCiego [Internet]. 2011 [citado 22 Feb 2013]; 17(2): [aprox. 8 p.]. Disponible en: http://bvs.sld.cu/revistas/mciego/vol17_02_2011/pdf/T6.pdf
Tomás Alonso F, Garmendia ML, De Aguirre M, Searle J. Análisis de la tendencia de la mortalidad por cirrosis hepática en Chile: Años 1990 a 2007. Rev Med Chile. 2010; 138: 1253-1258.
Cuba. Ministerio de Salud Pública. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2011 [Internet]. 2012 [citado 27 Feb 2013] [aprox. 35 pantallas]. Disponible en: http://files.sld.cu/dne/files/2012/04/anuario-2011-e.pdf
Rodríguez Magallán A, Valencia Romero HS, Trinidad Altamirano J. Etiología y complicaciones de la cirrosis hepática en el Hospital “Juárez” de México. Rev Hosp Juarez Mex. 2008; 75(4):247-56.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol [Internet]. 2011 [citado 27 Feb 2013]. [aprox. 41 pantallas]. Disponible en: http://www.easl.eu/assets/application/files/4a7bd873f9cccbf_file.pdf
Fajardo González MH, Arce Núñez M, Medina Garrido Y, Esteva Carral L, Osorio Pagola MF. Comportamiento de la cirrosis hepática en el hospital "Arnaldo Milián Castro" de julio de 2007 a marzo de 2009. Medisur [Internet]. 2010 [citado 22 Feb 2013]; 8(4): [aprox 9 p.]. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1727-897X2010000400007&script=sci_arttext
Forester J, Dumortier J, Guillaud O, Ecochard M, Roman S, Boillot O, et al. Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests. Eur J Gastroenterol Hepatol. 2010; 22:532–540.
Aguilar I, Feja C, Compés ML, Rabanaque MJ, Esteban M, Alcalá T, et al. Desigualdades y mortalidad por cirrosis en varones (Zaragoza, 1996-2003). Gac Sanit. 2011; 25(2):139–145.
Maldonado López CJ, Jiménez Saab NG, Sánchez Hernández G. Hipoalbuminemia como factor de riesgo para hemorragia del tubo digestivo alto en pacientes con insuficiencia hepática Child B. Med Int Mex. 2012; 28(4):319-324.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatol. 2009; 49(4):1335-1374.
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a DNA clone derive from a blood-borne non-A, non-B viral hepatitis. Science. 1989; 244:359-62.
Castellanos Fernández MI. Importancia de la desnutrición en el pronóstico del paciente con cirrosis hepática [Internet]. 2010 [citado 27 Feb 2013] [aprox. 35 pantallas]. Disponible en: http://tesis.repo.sld.cu/248/
Garcia Tsao G, Lim J. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the department of veteran’s affairs hepatitis C resource center program and the national hepatitis C program. Am J Gastroenterol. 2009; 104:1802–1829.
European Association for the Study of the Liver. EASL Clinical Practical Guidelines: management of alcoholic liver disease. J Hepatol. 2012; 57: 399–420.
Garcia Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (Stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology. 2010; 51(4): 1445-1449.
Campos Varela I, Castells Ll. Puntuaciones de pronóstico de la cirrosis. Gastroenterol Hepatol. 2008; 31(7):439-46.
Calzadilla Bertot L, Vilar Gómez E, Lincheta Enriquez L. Modelos pronósticos para la cirrosis hepática. Rev Cubana Med. 2011; 50(2):190-201.
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
